Background/Aims: Acute myeloid leukemia (AML) remains a hematologic malignancy with poor survival and a high risk of relapse, which is mainly caused by the emergence of multidrug resistance (MDR). The identification of novel agents to improve therapeutic strategies becomes important priority for AML treatment. It has been shown that emodin has therapeutic effects on many kinds of human malignant tumors. In this study, we investigated the anti-leukemia effects of emodin alone or in combination with cytarabine (Ara-C) on multidrug-resistant AML HL-60/ADR cells and in a mouse xenograft model of human highly tumorigenic AML HL-60/H3 cells. The underlying mechanism was also addressed. Methods: Cell viability after treatment was measured by MTT assay. The DNA fragmentation assay, Annexin V-PE/7-AAD, AO/EB staining, and electron microscopy were introduced to assess the apoptotic induction effects. Changes in protein expression in the Akt and ERK signaling pathways were determined by western blotting. In vivo antileukemia effects on HL-60/H3 xenograft model and overall mouse survival outcomes were further analyzed in this study. Results: Emodin dose-dependently induced growth inhibition and apoptotic effects in resistant HL-60/ADR cells in vitro as well as in the HL-60/H3 xenograft models in vivo. Moreover, emodin significantly enhanced chemosensitivity of AML cells to Ara-C, inhibited leukemic cell growth, and improved survival in the mouse xenograft model of AML. Dual targeting of Akt and ERK signaling pathways
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Introduction
Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by immature myeloid cell proliferation and bone marrow failure [1] . Intensive anthracycline and cytarabine (Ara-C)-based combination chemotherapy has been the backbone of AML treatment in recent decades [2, 3] . However, AML is still associated with a dismal prognosis [4] . The emergence of multidrug resistance (MDR) to multiple chemotherapeutic agents is a major hurdle in the successful treatment of AML. Discoveries of novel therapeutic agents, which can be used to overcome MDR, become a challenge in the clinic. A lot of traditional Chinese medicine and their active extracts have shown anti-leukemia activities. Many of them have been widely used for the treatment of leukemia patients, such as Taxol, Vincristine, Homoharringtonine and Arsenic Trioxide [5] [6] [7] [8] .
Emodin (1, 3, 8-trihydroxy-6-methyl-anthraquinone) is a natural anthraquinone compound extracted from various Chinese herbs including Rheum officinale and Polygonam cuspidatum medicine. In vitro and in vivo studies have demonstrated that emodin may be a suitable candidate for cancer treatment [9] [10] [11] [12] [13] . A recent report showed that emodin can effectively reverse the resistance of lung cancer H69AR cells to doxorubicin by inhibition epithelialmesenchymal transition [14] . Emodin reverses adriamycin resistance in chronic myelogenous leukemia K562/ADM cells by downregulation of P-gp protein [15] . The effects of emodin and its combination with chemotherapeutic agents on resistant AML cells are unclear. In the present study, we administered emodin alone or combined with Ara-C in both multi-drug resistant AML HL-60/ADR cells in vitro and in a xenograft model of human highly tumorigenic AML HL-60/H3 cells in vivo. We demonstrate that emodin could inhibit proliferation and induce apoptosis in different leukemia cell lines including in HL-60/ADR cells. Of note, emodin at low dose potentially enhanced sensitivities to Ara-C in both HL-60/ADR cells and HL-60/H3 cells. The blockage of Akt and ERK signaling pathway played a critical role for the observed therapeutic effects of emodin in vitro and in vivo. These findings provide new insights into overcoming resistance in AML cells and demonstrate an attractive novel strategy in future treatment of AML.
Materials and Methods
Chemicals and reagents
Emodin (C 15 H 10 O 5 , MW: 446.35, HPLC-determined purity > 98%) was obtained from Nanjing Qingze Medical Technology Company (Nanjing, China). Adriamycin (ADR) was purchased from Pharmacia Italia S.P.A. Cytarabine (Ara-C) was obtained from Zhejiang Hisun Pharmaceutical Company (Taizhou, Zhejiang, China). The preparation and maintenance of the stock solutions of reagents were described previously [13] .
Cell lines and cell culture
The human multidrug resistant AML HL-60/ADR cell line and its parental HL-60 cell line were obtained from the Institute of Hematology, Chinese Academy of Medical Sciences. Human AML cell line (U937), human lymphocytic leukemia and lymphoma cell lines (CEM, Jurkat, Molt-4, CA46) were purchased from CCTCC (China Center for Type Culture Collection, Wuhan, Hubei, China). HL-60 cells were inoculated subcutaneously into nude mice to establish a human leukemia xenograft model. The highly tumorigenic leukemia cell line HL-60/H3 cells were isolated from the HL-60 xenografted tumor cells in nude mice. All leukemia cell lines were routinely cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. HL-60/ADR cells were maintained in RPMI-1640 medium with 0.2-0.8 µg/ml ADR and were grown in ADR-free culture medium at least two weeks for each experiment. 5 /ml cells in RPMI 1640 medium with 10% fetal bovine serum were plated in 6-well plates. After 24 h of incubation with emodin, Ara-C, or emodin plus Ara-C, cells were harvested and washed with PBS, and then stained with Annexin V-PE/7-AAD (Becton Dickinson, NJ, USA) according to the manufacturer's instruction. The apoptotic cells were quantified by flow cytometry. For Acridine Orange/ Ethidium Bromide (AO/EB) staining, 5 μl of unfixed cells were loaded using 95 μl of freshly prepared AO/ EB staining solution (100 μg/ml) and immediately observed under a Nikon fluorescence microscope (Nikon Inc., Japan) within 20 min.
DNA Fragmentation Assay
HL-60/ADR cells were exposed to different concentrations of emodin for 72 h. Cells were harvested and washed with PBS. DNA extraction was performed according to the manufacturer's protocol. DNA was visualized by Goldview Nucleic Acid Stain on Gel Image Analysis System (Peiqing, JS-380A, Shanghai, China).
Western blot analysis HL-60/ADR cells were exposed to emodin at varying concentrations and time points in vitro. Cells were collected and protein was purified after treatment. For the in vivo study, tumor tissues of approximately 100 mg per mouse were minced and homogenized on ice. The tumor tissue protein was purified. Western blotting was performed as described previously [16, 17] . Quantification of the band densitometry was performed by Quantity One Version 4.6.2 Software (BIO-RAD, Hercules, CA, USA). Primary antibodies against human Procaspase-9, Procaspase-3, Bid, poly (ADP-ribose) polymerase (PARP), p-Akt (Ser473), Akt, p-mTOR(Ser2448), mTOR , p-4E-BP1 (Thr70) and p-p70S6k(Thr389) were obtained from Cell Signaling Technology (Beverly, MA, USA). Bcl-2, Bax, ERK, p-ERK1/2(Thr202/Tyr204) and β-Actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rapamycin was obtained from Calbiochem EMD Millipore Corporation (Billerica, MA, USA). LY294002 and PD98059 were obtained from Sigma-Aldrich Corporation (St. Louis, MO, USA).
In vivo anti-tumor growth model and overall survival outcomes BALB/C-nude mice (SPF) were purchased from Shanghai Slac Laboratory Animal Co., Ltd.. All mice were maintained in SPF conditions in the animal facility at Fujian Medical University. Animal studies were performed according to the protocol approved by the Ethics Committee of Institutional Animal Care and Use in Fujian Medical University. Six-to eight-week-old nude mice were subjected to 100 mg/kg/d cyclophosphamide by intraperitoneal (ip) injection for two days. Forty-eight hours after preconditioning, around 1.5×10
7 HL-60/H3 cells were subcutaneously injected into the right flank of nude mice. When the tumor volume reached approximately 100 mm 3 , the tumor-bearing mice were treated with either vehicle alone (n = 6), 20 mg/kg (n = 6)，40 mg/kg (n = 6) of emodin，or the sequential combination of emodin and Ara-C (n = 6, 20 mg/kg emodin treatment prior to 2 mg/kg Ara-C injection). All mice were administered by i.p. injections once a day for 14 days. Tumor size was measured every 7 days with a caliper (tumor volume = shortest diameter 2 ×longest diameter/2). Mouse whole blood was collected at 24 h after the last administration. Tumor tissues and organs were carefully excised. Tumor suppression rate (%) = (1-mean tumor weight in experimental group/mean tumor weight in control group) ×100%.
The experiment was repeated and animals were monitored every day. The survival rate and survival time were evaluated. The endpoint of follow-up for each mouse was determined by the following conditions: lack of response to manual stimulation, immobility, and/or inability to eat or drink. The remaining mice were euthanized at the 70th day after the treatment.
Mouse blood count
Whole blood of mice from each group was collected into sterile tubes containing K 2 EDTA for hematological studies before animals were sacrificed. Peripheral leukocytes, erythrocytes, platelets, and hemoglobin concentration were measured by using an automatic animal blood counter (HEMAVET 950, Drew Scientific Inc, Miami Lakes, USA).
Histopathological examination
Mice were sacrificed by cervical dislocation after last administration. Main organs, including heart, liver, spleen, lung, kidney, intestine, and tumor tissues isolated from each group were fixed in paraformaldehyde solution, embedded in paraffin, and stained with hematoxylin-eosin. The structure and internal organization were observed by light microscopy.
Electron microscopy observation
Briefly, approximately 1 mm 3 volume of newly isolated tumor tissue was fixed at 4°C in 3% glutaraldehyde solution before treatment with 1% osmium tetroxide. Samples were washed prior to successive dehydration and emersion in propylene oxide:resin (1:1), followed by resin only. Samples were polymerized before sectioning and staining with lead citrate/uranylacetate for imaging under transmission electron microscopy (Hu-12A, Hitachi, Japan).
Statistical analysis
Results are presented as mean ± standard deviation, and statistical comparisons of experimental groups were evaluated by Student's t test using GraphPad Prism (version 5.0). Mouse survival curves were constructed by the KaplanMeier methodology and compared by the log-rank test. P < 0.05 was considered as significant difference.
Results
Emodin inhibits proliferation and induces apoptosis in different leukemic cells
MTT assay was used to examine the growth inhibitory effects in eight independent human leukemic cell lines including U937, CEM, Molt-4, Jurkat, CA46, HL-60, HL-60/ H3, and multidrug resistant HL-60/ADR cells. Emodin inhibits the growth of myeloid leukemia cells as well as that of lymphocytic leukemia cells. The anti-proliferation effects of emodin in various leukemia cell lines were presented in a dose-dependent way (Fig.1A) . The IC50 value was between 22.28 ± 3.07 µM and 39.17 ± 1.69 µM. 1D) . Consistently, the DNA fragmentation assay revealed characteristic ladder patterns in emodin-treated HL-60/ ADR cells. The DNA ladder appeared more evident in high concentration of emodin exposure groups (Fig. 1E) . Cells were harvested and then proteins were extracted. Western blotting was performed to visualize the expression levels of 116 kDa PARP, 85 kDa PARP, procaspase-3, cleaved caspase-3, procaspase-9, Bid, Bax, phosphorylation of Akt, mTOR, 4E-BP1, p-70S6K, and ERK proteins along with β-actin as loading controls. The band intensity was quantified. Protein expression levels are represented as percentage change from untreated control levels, which were set to 100% (1.00). The lower set of numbers indicates the relative protein level. (E) HL-60/ADR cells were treated with emodin (8 and 80 µM), LY294002 (40 µM), rapamycin (1.0 µM) and PD98059 (20 µM) for 12 h. Proteins were extracted from harvested cells. Western blot analysis was performed to determine the expression levels of p-Akt, p-mTOR, p-4E-BP1, p-p70S6K, and p-ERK proteins. All experiments were repeated three times. 
Emodin induces activation of the caspase-dependent apoptotic pathway and suppresses activation of the Akt and ERK signaling pathways in HL-60/ADR cells
To explore the underlying mechanisms of emodin-induced apoptosis in HL-60/ADR cells, we further examined several effectors of apoptosis such as the Bcl-2 family and executioner caspases. Western blotting results showed that emodin dramatically reduced the expression levels of Procaspase-3 and Procaspase-9 and markedly induced the cleavage of Caspase-3 and PARP in a dose-and time-dependent manner. Concomitantly, the expression level of Bid, one of the anti-apoptotic protein Bcl-2 family members, was decreased while the proapoptotic Bax protein expression was induced with longer incubation time and higher dose exposure of emodin in HL-60/ADR cells ( Fig. 2A and B) .
The activation of the Akt signaling pathway is frequently observed in acute leukemia samples and sustains leukemic cell growth [18, 19] . ERK plays an important role in cell proliferation and differentiation, and its activation is associated with MDR development [20] [21] [22] . We therefore analyzed whether emodin affects the Akt and ERK signaling pathways. The results demonstrated that emodin dose-and time-dependently abrogated phosphorylation of Akt and mTOR in HL-60/ADR cells. In parallel, emodin also inhibited mTOR downstream targeted proteins p-4E-BP1 and p-p70S6K in HL-60/ADR cells in the same manner ( Fig. 2C  and D) . Of note, emodin remarkably decreased the phosphorylation of ERK both in doseand time-dependent manners. To further confirm the effects of emodin on dual targeting of the Akt and ERK signaling pathways, HL-60/ADR cells were conditioned in parallel with either two different doses of emodin, the PI3K/Akt inhibitor (LY294002), the mTOR inhibitor (Rapamycin), or the MAPK inhibitor (PD98059), respectively. Compared with the untreated group and the lower dose of emodin treatment group, the inhibitory effects on the phosporylation of Akt, mTOR, 4E-BP1 and p70S6K induced by 80 µM emodin were as strong Cell
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as those following LY294002 and Rapamycin treatment. Moreover, high concentration of emodin similarly down-regulated the p-ERK protein compared with PD98059 (Fig. 2E) .
These results indicate the dual targeting of the Akt and ERK pathways is involved in emodinmediated anti-leukemia activity.
Emodin increases sensitivity of HL-60/ADR cells to Ara-C
Enhancements of the sensitivity of resistant HL-60/ADR cells to Ara-C were also measured by MTT assay. Emodin at 5 µM or 10 µM alone only induced mild growth inhibition in HL-60/ADR cells. Notably, the administration of emodin along with increasing doses of Ara-C significantly enhanced proliferation inhibition in HL-60/ADR cells. The mean level of growth inhibition was 5.63 ± 0.52% and 40.96 ± 4.69% in the 0.63 µM and 1.25 µM Ara-C mono-treament groups, respectively. When 5 µM emodin was combined with 0.63 µM and 1.25 µM Ara-C, the suppression level was increased up to 35.29 ± 1.41% and 59.17 ± 15.07% in the combination group in HL-60/ADR cells, respectively. When applied higher dose of emodin (10 µM) to the 0.63 µM and 1.25 µM Ara-C mono-treatment group, the inhibitory level was significantly raised to 45.12 ± 5.15% and 68.33 ± 2.02% in the co-treatment groups, respectively ( P = 0.0006 and P = 0.002 vs. Ara-C alone, respectively, Fig. 3A) .
To investigate whether low dose emodin has the potential to enhance Ara-C-induced apoptosis in HL-60/ADR cells, the combination treatment of 10 µM emodin plus 2.0 µM Ara-C was performed in this study. Results showed that only minimal early apoptosis was evident in HL-60/ADR cells in the presence of 10 µM emodin for 24 h, which was equivalent to that of the untreated control (P = 0.35). However, the percentage of early apoptotic cells dramatically increased up to 30.47 ± 2.36% in the co-treatment group, which was 2-fold higher than that in the Ara-C only-treated group (P = 0.003) (Fig. 3B and 3C ).
Emodin inhibits xenograft growth and enhances anti-leukemia activities of Ara-C in the HL-60/H3 xenograft model
The anti-leukemic potential of emodin alone or in combination with Ara-C in vivo was tested using a HL-60/H3 xenograft model in nude mice. As shown in Fig. 4A -C, the growth of HL-60/H3 tumors in each conditioning group was remarkably suppressed by comparison with that in the vehicle control group after 14 days of treatment. The average tumor volume of the combination group was 0.37 ± 0.05 cm 3 (n = 6), which was significantly smaller than that in the vehicle alone (n = 6) and 20 mg/kg (n = 6) or 40 mg/kg (n = 6) of emodin-or Ara-C-treated groups (n = 6). Twenty-four hours after the last administration, tumor tissues in each group were carefully excised and weighed. The mean tumor weight in the vehicle control group was 3.16 ± 0.88 g (n = 6). Emodin combined with Ara-C-treated mice displayed dramatic inhibition of leukemia cell expansion. The mean tumor weight in the combination group was 0.29 ± 0.07 g (n = 6), which was significantly lower than that in the emodin, Ara-C, and vehicle control groups. The tumor inhibitory rate was 32.2%, 52.5% and 77.4% in 20 mg/kg emodin, 40 mg/kg emodin and Ara-C alone groups, respectively. However, the combination of emodin and Ara-C presented much more inhibitory effects on mouse leukemia xenograft model. The tumor inhibition was as high as 90.9% following emodin plus Ara-C administration. These results provide in vivo evidence of AML cells in response to emodin treatment. The combination of the conventional drug Ara-C and the novel compound emodin may exert synergistic anti-leukemic effects.
Emodin combined with Ara-C induces apoptosis in vivo via inactivation of the Akt and ERK pathways
The ultrastructural changes in leukemia cells in the xenograft model were further assessed under the microscope. Emodin in combination with Ara-C treatment triggered more apoptotic cells in the tumor tissues. These cells exhibited morphological features of cell apoptosis, including nuclear condensation, nuclear fragmentation, and apoptotic body formation. Tumor cells from Ara-C-treated mice displayed necrosis phenotype features, such as disruption of ultrastructural integrity and nuclear degeneration. By contrast, HL-60/H3 cells maintaining ultrastructural integrity were densely distributed in the vehicle xenograft tumor tissues (Fig. 4D) .
The molecular mechanism underlying susceptibility to apoptosis of HL-60/H3 cells in vivo was analyzed. Western blotting results showed that the combination of 20 mg/kg emodin and 2 mg/kg Ara-C resulted in remarkable down-regulation of expression levels of p-Akt, p-mTOR and p-ERK. Consistently, anti-apoptotic Bcl-2 protein in the tumor tissues was also markedly inhibited following combination treatment (Fig. 4E) . These findings further verified that emodin plus Ara-C might exert more efficient anti-leukemic effects. Both the Akt and ERK pathways were identified as potential therapeutic targets following co-treatment.
Histopathological and hematological examination
In Fig. 5A , HL-60/H3 cells in subcutaneous tumor tissues in the vehicle control group were round or elliptical and of different sizes with large stained nuclei. Few tumor cells were found in tumor tissues from differently conditioned mice exhibiting morphological changes, such as cell shrinkage, nuclear condensation, or remaining the nude nuclear. Some erythrocytes were present on the tissue sections from conditioned mice. Focal necrosis of tumor cells was observed in the higher dose emodin treatment group. The increasing 
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numbers of fibroblast cells and collagen fiber deposition were frequently observed in the tumor tissues from combination treatment mice. Hematological examinations showed that leukocyte counts were only modestly decreased at low dose emodin alone (P = 0.09), but significantly decreased at either high dose emodin, Ara-C alone, or low dose emodin plus Ara-C when compared with those of vehicle control mice. There were statistically significant increases in both erythrocyte counts and hemoglobin levels following emodin combined Ara-C treatment. No significant effects on platelet counts were found in any regimen (Fig. 5B) . After the last administration, the important organs including the heart, liver, spleen, lung, kidney, and intestine were also well excised from the xenograft models in each group. There were no significant histological changes in any organ from the treated mice (data not shown).
Survival analysis
The different regimens were well tolerated by the HL-60/H3 xenograft nude mice, and no significant side-effects were found during the 14 day administration. As shown in Fig.  6 , all of the animals survived at the 35th day after the initial administration. However, the survival rate was less than 50% at the 70th day, which was 16.7% (1/6), 33.3% (2/6), and 33.3% (2/6)in the vehicle control, 20 mg/kg emodin, and 2 mg/kg Ara-C groups, respectively. In comparison, more than half of the mice remained alive in the 40 mg/kg emodin group and the combination group at the end of 70 day observation (survival rate: 66.7% and 83.3%, respectively). The log rank test results showed that both the 40 mg/kg emodin and 
Fig. 6. Emodin and its combination with
Ara-C improve AML xenograft mouse survival. Mouse xenograft models of AML were monitored every day after initial administration. The survival rate and survival time were evaluated in each group. *P<0.05, **P<0.01 vs. control. 
Discussion
Plant-derived natural products have garnered considerable attention in recent years due to the remarkable pharmacological properties in hematological malignancies [5, 9, 23] . Here, we presented the anti-leukemic effects of emodin and its combination with Ara-C on multidrug-resistant HL-60/ADR cells. And we also demonstrated the first report about the in vivo therapeutic effects based on a murine xenograft model of AML using emodin and its combination treatment regimen. In addition, we further confirmed that the dual suppression of constitutive activation of the Akt and ERK pathways might be involved in growth inhibition in AML cells by emodin.
Multidrug resistance (MDR), by which leukemia cells are resistant to multiple chemotherapeutic agents, is a serious problem correlated with poorer clinical outcome in acute leukemia patients. Novel drugs, which could overcome MDR, are of great importance for the treatment of AML patients. Emodin, a natural anthraquinone compound extracted from traditional Chinese medicine, has been shown to have multiple anti-tumor activities [9] [10] [11] [12] [13] [14] [15] . The administration of emodin in pregnant mice has been previously reported, which indicated its high safety [24] . Liu et al. showed that emodin could be used as a sensitizer in the gemcitabine-resistant pancreatic cancer cells [25] . HL-60/ADR cells overexpressed multidrug resistance-associated protein (MRP1) are highly resistant to different chemotherapeutic agents [13, 26] . Our results showed that emodin dose-dependently inhibited proliferation and induced apoptosis in HL-60/ADR cells. Notably, the IC50 value of emodin in resistant HL-60/ADR cells was similar to that in sensitive HL-60 cells. So we designed and synthesized a series of derivatives based on the anthraquinone structure of emodin. Similar pharmacological effects as those induced by emodin were found on resistant leukemia cells. One of the most important mechanisms was due to the unique anthraquinone structure of emodin, which facilitates the capture and delivery of electrons from the electron respiratory chain to oxygen to enhance the generation of reactive oxygen species (ROSs) in leukemia cells, including in those with the MDR phenotype. Emodin as ROS-inducer involved in the process of tumor cell growth suppression and apoptosis has been explored in previous studies [9, 27] .
Daunomycin (DNR) in combination with Ara-C (DA regimen) was the typical regimen for induction remission in AML over the last decades, and the overall 5-year survival remains poor, being < 30% [28, 29] .Recent regimen improvements include the replacement of DNR with the other anthracycline agents and the dose adjustment of Ara-C. In this study, we replaced DNR with the traditional Chinese medicine emodin, which has similar anthraquinone chemo-structure. We found that low dose emodin could significantly enhance the sensitivity of resistant HL-60/ADR cells to Ara-C. The percentage of apoptotic cells markedly increased up to more than 2-fold compared to single Ara-C-treated cells. These data indicate that emodin may be a novel inducer of apoptosis and a promising candidate as a chemo-sensitizer for drug resistant AML cells.
Cha et al. in M. D. Anderson Cancer Center showed that emodin could directly target androgen receptor (AR) to suppress prostate cancer cell growth in vitro and prolong the survival of C3 (1)/SV40 transgenic mice [30] . A recent study also showed that emodin may suppress hepatocellular carcinoma growth and improve liver and kidney function in experimental mice without an obvious change in body weight, indicating that emodin may be an effective and safe drug for the treatment of hepatocellular carcinoma [31] . To see whether emodin has the potential to improve AML therapy in vivo, we established an AML xenograft mouse model with highly tumorigenic leukemia HL-60/H3 cells. As we know, the DA regimen is widely used in AML therapy in the clinic. In the in vivo study, we examined emodin and Ara-C effects to AML. The tumor growth in HL-60/H3 xenograft mice was significantly suppressed in an emodin dose-dependent manner after daily injection of emodin for 14 days. Importantly, the regimen of emodin plus Ara-C presented the best anti-leukemic effects in the HL-60/H3 xenograft mice. More apoptotic leukemia cells were induced by the combination therapy. Moreover, emodin administration was well tolerated by the nude mice, and no severe adverse effects were shown in hematological and histopathological examinations. Survival data in our study demonstrated that high dose emodin could increase the survival rates of HL-60/H3 xenograft mice. It presented better therapeutic effect on reducing tumor burden when low dose emodin was administered with low dose Ara-C, and significantly improved the mouse survival. An in vivo xenograft chemotherapy model might show physiologically relevant responses to the drugs that parallel what is seen in the clinic. Based on the available data, this is the first study to demonstrate the in vivo therapeutic relevance of emodin in a murine xenograft model of AML. The treatment regimen using combined emodin and Ara-C administration may be an appealing strategy for AML therapy.
The constitutive activation of the Akt pathway plays a critical role in the progression of leukemia cases [18, 19] . Akt activation indirectly promotes transcription of antiapoptotic genes, while it directly phosphorylates the downstream target, mTOR. Brown et al. showed that emodin and docosahexaenoic acid (DHA) potently increase arsenic trioxide interferon-α-induced cell death of HTLV-I-transformed cells by generation of ROSs and inhibition of Akt and AP-1(Jun D and JAB1), while the administration did not significantly change the activities of the normal peripheral blood mononuclear cells (PBMCs) [9] . It has been reported that ERK activation is associated with the MDR development [20] [21] [22] 32] . Whether emodin and its combination therapy affect the activation of Akt and ERK was also addressed in this study. Western blot results showed that the activation of signaling molecules, such as p-Akt, p-mTOR and p-ERK1/2 in HL-60/ADR cells was markedly suppressed by emodin in a time-and dose-dependent pattern. The blocking activation of Akt and ERK of emodin in HL-60/ADR cells was further confirmed by comparison with PI3K/Akt inhibitor LY294002, mTOR inhibitor rapamycin, and MAPK inhibitor PD98059. Moreover, we also found the phosphorylation of both Akt and ERK were significantly abrogated in the xenograft model of AML following emodin plus Ara-C administration. Low dose Ara-C alone did not affect the activation of Akt and ERK, which was consistent with the conclusions previously reported by Sampath Olsen [33] . Together, our in vitro and in vivo experimental results demonstrate that anti-proliferative/pro-apoptotic effects of emodin are mediated at least in part through the dual abrogation of the Akt and ERK signaling pathways in AML cells. Leukemia stem cells (LSCs) are associated with chemotherapy resistance and AML relapse [34] [35] [36] . Strategies for the eradication of LSCs may efficiently prevent the recurrence of AML. Thus, it is worthwhile to further investigate whether emodin and its derivatives may target LSCs.
Overall, these findings indicate that emodin and its combination with Ara-C, as a promising new therapeutic paradigm, may elicit more robust responses and provide a novel strategy for AML treatment.
